Otsuka and Lundbeck enter "historic" CNS alliance as patent expiries loom
This article was originally published in Scrip
Otsuka Pharmaceutical and Lundbeck have entered into what they describe as an "historic" major global alliance in the CNS area worth up to $1.8 billion to the Japanese firm that will initially focus on a joint development and commercialisation programme for two Otsuka products for schizophrenia.
You may also be interested in...
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.